Thermo Fisher Scientific partners with Medidata Acorn AI for clinical research advancement
pharmafile | February 8, 2022 | News story | Manufacturing and Production |
Thermo Fisher Scientific has announced a multiyear partnership with medidata Acorn AI, a Dassault Systemes company leading the digital transformation of life sciences.
Through this partnership, the PPD clinical research business of Thermo Fisher has collaborated with Medidata to develop PPD TrueCast, a comprehensive enterprise application combining extensive patient recruitment and site performance data with predictive models and advanced analytics.
This platform offers the opportunity for the optimisation of clinical research site selection, trial enrollment, and study cycle times.
“The clinical trial industry continues to demand new tools in big data and predictive analytics to improve trial planning and execution and accelerate clinical trials,” said David M Johnston, PhD, senior vice president and president, clinical research, Thermo Fisher Scientific. “As a result of the vast site-level data amassed by PPD and Medidata, customers now have even greater visibility into how a trial is performing for any study our clinical research business is helping them run. We already have successfully deployed these machine learning-based insights to give us a competitive site selection advantage in the crowded trial landscape.”
“AI and advanced analytics play an increasingly critical role in a rapidly changing clinical trial environment,” said Fareed Melhem, senior vice president, Medidata Acorn AI. “We’re delighted to be working side by side with Thermo Fisher’s clinical research business to combine our technology, data and expertise. Together, we are now offering companies new ways to rethink their clinical trials through access to live, cross-industry site performance data.”
Lina Adams
